Record Quarterly Revenue
GXO achieved record quarterly revenue of $3.4 billion with organic revenue growth across every region. This marks an 8% increase year-over-year, with 4% being organic growth.
Strong Adjusted EBITDA Growth
Adjusted EBITDA grew by 13% from last year to $251 million, and margins expanded by 100 basis points sequentially and 30 basis points year-over-year.
New Business Wins
GXO secured $280 million in new business wins, up 24% year-over-year, contributing to over $800 million in year-to-date wins, with a clear line of sight to exceed $1 billion in 2025.
Wincanton Integration
The integration of Wincanton is underway, expected to unlock growth opportunities in Europe, particularly in industrial, aerospace, and defense sectors.
Strong Sales Pipeline
GXO's $2.3 billion sales pipeline is robust and well diversified across regions and verticals, with increased activity in strategic sectors like life sciences and aerospace and defense.
Successful NHS Contract Launch
The $2.5 billion, 10-year contract with the U.K.'s NHS supply chain launched flawlessly in early October, with potential for further expansion.